# EDGAR Filing Document

**Accession Number:** 0001114448
**File Stem:** 0001171843-23-001905
**Filing Date:** 2023-3
**Character Count:** 23004
**Document Hash:** aabd26ba4146025fb25054b3e52e9a6c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-23-001905.hdr.sgml**: 20230327

**ACCESSION NUMBER**: 0001171843-23-001905

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230327

**FILED AS OF DATE**: 20230327

**DATE AS OF CHANGE**: 20230327

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NOVARTIS AG
- **CENTRAL INDEX KEY:** 0001114448
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15024
- **FILM NUMBER:** 23761488

**BUSINESS ADDRESS:**
- **STREET 1:** LICHTSTRASSE 35
- **CITY:** BASEL
- **STATE:** V8
- **ZIP:** CH 4056
- **BUSINESS PHONE:** 01141613241111

**MAIL ADDRESS:**
- **STREET 1:** LICHTSTRASSE 35
- **CITY:** BASEL
- **STATE:** V8
- **ZIP:** CH 4056

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 or 15d-16 OF**

**THE SECURITIES EXCHANGE ACT OF 1934**

**Report on Form 6-K dated March 27, 2023**

**(Commission File No. 1-15024)**

____________________

**Novartis AG**

(Name of Registrant)

**Lichtstrasse 35**

**4056 Basel**

**Switzerland**

(Address of Principal Executive Offices)

____________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

---

| | |
|:---|:---|
| **Form 20-F: ☒** | Form 40-F: ☐ |

---

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

---

| | |
|:---|:---|
| Yes: ☐ | **No**: **☒** |

---

---

| | |
|:---|:---|
| ![](logo.jpg) | **Novartis International AG<br> Novartis Global Communications**<br> CH-4002 Basel<br> Switzerland<br>https://www.novartis.com<br> https://twitter.com/novartisnews |

---

**MEDIA & INVESTOR RELEASE**

**Novartis Kisqali** **<sup>®</sup> Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer**

**Ad hoc announcement pursuant to Art. 53 LR**

• *Kisqali plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting<sup>1</sup>* 

 

• *NATALEE is the first and only positive Phase III study of a CDK4/6 inhibitor demonstrating consistent benefit in a broad population of patients with stage II and III HR+/HER2- early breast cancer (EBC) at risk of recurrence, including those with no nodal involvement* 

 

• *Approximately 30-60% of people with HR+/HER2- stage II and III EBC treated with ET only remain at risk of breast cancer recurrence<sup>2</sup>* 

 

• *NATALEE results will be presented at an upcoming medical meeting and submitted to regulatory authorities worldwide* 

**Basel, March 27, 2023** — Novartis today announced positive topline results from an interim analysis of NATALEE, a Phase III trial evaluating Kisqali® (ribociclib) plus endocrine therapy (ET) in a broad population of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC) at risk of recurrence<sup>1</sup>. The Independent Data Monitoring Committee recommended stopping the trial early as the primary endpoint of invasive disease-free survival (iDFS) has been met. Kisqali plus ET significantly reduced the risk of disease recurrence, compared to standard adjuvant ET alone, with consistent benefit in patients with stage II and stage III EBC regardless of nodal involvement<sup>1</sup>.

"While most patients are diagnosed and treated early with the aim to cure breast cancer, the risk of cancer returning, often as metastatic disease, peaks within three years after diagnosis, but never goes away completely," said Dennis J. Slamon, MD, Director of Clinical/Translational Research, University of California, Los Angeles Jonsson Comprehensive Cancer Center and Chairman and Executive Director of Translational Research In Oncology (TRIO) and NATALEE trial lead investigator. "There is a critical need for new, well-tolerated options that keep patients cancer-free without disrupting quality of life. The NATALEE trial, where ribociclib was given for three years plus ET, was designed with these unmet needs in mind, and it is extremely encouraging that this study met its primary endpoint."

Per the NATALEE study protocol, patient follow-up will continue to evaluate long-term outcomes, including overall survival<sup>1</sup>.

"The positive topline results from NATALEE represent a major milestone in our ambition to expand the benefits of Kisqali to patients with earlier stages of breast cancer, building on the heritage of this effective treatment in HR+/HER2- metastatic breast cancer," said Shreeram Aradhye, M.D., President, Global Drug Development and Chief Medical Officer, Novartis. "These data have the potential to be paradigm-shifting for patients at risk of recurrence, including those with no nodal involvement, who have limited well-tolerated options to prevent recurrence. Our teams are working on submissions to health authorities around the world with the hope to bring Kisqali to many more patients diagnosed with breast cancer."

These findings build on the legacy of Kisqali in metastatic breast cancer (MBC), where it has consistently demonstrated overall survival benefit while preserving or improving quality of life across three Phase III trials<sup>3-14</sup>. Updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for breast cancer, released in January 2023, recommend ribociclib (Kisqali) as the only Category 1 preferred CDK4/6 inhibitor for first-line treatment of patients with HR+/HER2- MBC when combined with an aromatase inhibitor (AI)<sup>15</sup>.

**About NATALEE**

NATALEE is a global Phase III multi-center, randomized, open-label trial to evaluate the efficacy and safety of Kisqali with ET as adjuvant treatment versus ET alone in patients with HR+/HER2- EBC, being conducted in collaboration with Translational Research In Oncology (TRIO)<sup>1</sup>. The primary endpoint of NATALEE is iDFS as defined by the Standardized Definitions for Efficacy End Points (STEEP) criteria; secondary endpoints include safety, quality of life, and overall survival, among others. iDFS is a composite endpoint in EBC adjuvant trials, which incorporates locoregional relapse, ipsilateral and contralateral invasive breast cancer, distant recurrence, and types of new cancer events or death from any cause. Approximately 5,100 adult patients with HR+/HER2- EBC across 20 countries were randomized in the trial, including patients with tumor stages IIA (select patients), IIB or III, regardless of nodal involvement. NATALEE explored a lower starting dose (400 mg) of Kisqali than the dose approved for treatment in MBC (600 mg) with the goal to minimize disruptions to patient quality of life without compromising efficacy<sup>1</sup>.

**About Early Breast Cancer**

More than 90% of patients diagnosed with breast cancer have EBC<sup>2,16</sup>. Approximately 30-60% of people with HR+/HER2- stage II and III EBC treated with ET only remain at risk of breast cancer recurrence<sup>2</sup>. The risk of recurrence peaks within the first three years after initial diagnosis and continues over decades<sup>2</sup>. For many of these patients, there are currently no targeted therapeutic options outside of the standard chemotherapy and ET<sup>17</sup>.

#### About Kisqali<sup>®</sup> (ribociclib)
Kisqali has consistently demonstrated overall survival benefit while preserving or improving quality of life across three Phase III trials<sup>3-14</sup>. Updates to the NCCN Guidelines® for breast cancer, released in January 2023, recommend ribociclib (Kisqali) as the only Category 1 preferred CDK4/6 inhibitor for first-line treatment of patients with HR+/HER2- MBC when combined with an AI<sup>15</sup>. Additionally, Kisqali has the highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale, achieving a score of five out of five for first-line premenopausal patients with HR+/HER2- advanced breast cancer<sup>18</sup>. Further, Kisqali in combination with either letrozole or fulvestrant has uniquely, among other CDK4/6 inhibitors, received a score of four out of five for postmenopausal patients with HR+/HER2- advanced breast cancer treated in the first line<sup>19</sup>.

Kisqali has been approved in 99 countries worldwide, including by the United States Food and Drug Administration (FDA) and the European Commission. In the U.S., Kisqali is approved for the treatment of adult patients with HR+/HER2- advanced or metastatic breast cancer in combination with an AI as initial ET or fulvestrant as initial ET or following disease progression on ET in postmenopausal women or in men. In the EU, Kisqali is approved for the treatment of women with HR+/HER2- advanced or metastatic breast cancer in combination with either an AI or fulvestrant as initial ET or following disease progression. In pre- or perimenopausal women, the ET should be combined with a luteinizing hormone-releasing hormone agonist<sup>14</sup>.

Novartis is committed to continuing to study Kisqali in breast cancer. Novartis is collaborating with SOLTI, which is leading the HARMONIA study to test whether Kisqali changes tumor biology to enable a better response to ET compared to Ibrance®\* (palbociclib) for patients with metastatic HR+/HER2-, HER2-enriched subtype<sup>20</sup>, and with the Akershus University Hospital in Norway on the NEOLETRIB trial, a neoadjuvant Phase II trial studying the effects of Kisqali in HR+/HER2- EBC to discover the potentially unique underlying mechanism of action<sup>21</sup>. Novartis also plans to build on the findings from NATALEE with ADJUVANT WIDER, an open-label Phase IIIb trial evaluating Kisqali plus ET in a population of HR+/HER2- patients with stage II and III EBC that is closer to a real-world population.

Kisqali was developed by the Novartis Institutes for BioMedical Research (NIBR) under a research collaboration with Astex Pharmaceuticals.

Please see full Prescribing Information for Kisqali, available at www.Kisqali.com.

#### Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "remain," "potential," "will," "plans," "committed," "continue," "keep," "to evaluate," "evaluating," "ambition," "to expand," "should," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Kisqali plus endocrine therapy, or regarding potential future revenues from Kisqali plus endocrine therapy. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Kisqali plus endocrine therapy will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Kisqali plus endocrine therapy will be commercially successful in the future. In particular, our expectations regarding Kisqali plus endocrine therapy could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20- F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

#### About Novartis
Novartis is reimagining medicine to improve and extend people's lives. We deliver high-value medicines that alleviate society's greatest disease burdens through technology leadership in R&D and novel access approaches. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. About 106,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world. Find out more at https://www.novartis.com

Novartis is on Twitter. Sign up to follow @Novartis at **https://twitter.com/novartisnews**

For Novartis multimedia content, please visit **https://www.novartis.com/news/media-library**

For questions about the site or required registration, please contact media.relations@novartis.com

#### References
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Novartis Data on File. Novartis Pharmaceuticals: 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Pan, H, Gray, R, Braybrooke, J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine
therapy at 5 years. *N Engl J Med.* Nov 2017;377(19):1836-1846. 10.1056/NEJMoa1701830

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Yardley DA, Yap YS, et al. Pooled exploratory analysis of survival in patients
(pts) with HR+/HER2- advanced breast cancer (ABC) and visceral metastases (mets) treated with ribociclib (RIB) + endocrine therapy (ET)
in the MONALEESA (ML) trials. Poster presented at the European Society of Medical Oncology Congress. September 9 -13, 2022. Paris, France.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. Neven P, Fasching PA, et al. Updated overall survival (OS) results from the first -line (1L) population
in the Phase III MONALEESA-3 trial of postmenopausal patients with HR+/HER2 - advanced breast cancer (ABC) treated with ribociclib (RIB)
+ fulvestr ant (FUL). Mini oral presented at the European Society for Medical Oncology Breast Cancer Congress. May 4, 2022. Patis, France.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall Survival with Ribociclib plus Letrozole in Advanced
Breast Cancer. *New England Journal of Medicine*. 2022;386(10):942-950. doi:10.1056/NEJMoa2114663

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. Hortobagyi, et al. Overall survival (OS) results from the phase III MONALEESA (ML)-2 trial of postmenopausal
patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer (ABC)
treated with endocrine the rapy (ET) ± ribociclib. Proffered paper presented at the European Society of Medical Oncology Congress,
September 16-21, 2021. Lugano, Switzerland.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. Im S-A, Lu Y-S, Bardia A, et al. Overall survival with ribociclib plus endocrine
therapy in breast cancer. *New England Journal of Medicine*. 2019;381(4):307-316. doi:10.1056/nejmoa1903765

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus
Fulvestrant in Advanced Breast Cancer. *New England Journal of Medicine*. 2020;382(6):514-524. doi:10.1056/NEJMoa1911149

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. Slamon, DJ, Neven P, Chia S, et al. Overall survival (OS) results of the
Phase III MONALEESA -3 trial of postmenopausal patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor
2–negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). Presented at the
European Society of Medical Oncology Congress, September 29, 2019, Barcelona, Spain.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. Slamon D, Neven P, Chia S, et al. Updated overall survival (OS) results from the Phase III MONALEESA-3
trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib
(RIB. Presented at the American Society of Clinical Oncology Annual Meeting, June 5, 2021. Chicago, USA.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. Tripathy D, Im S-A, Colleoni M, et al. Updated overall survival (OS) results from the phase III MONALEESA-7
trial of pre- or perimenopausal patients with HR+/HER2- advanced breast cancer (ABC) treated with endocrine therapy (ET) ±
ribociclib. Presented at the San Antoni o Breast Cancer Symposium, December 9, 2020. Texas, USA.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. Yardley, D, Nusch A, Yap YS, et al. Overall survival (OS) in patients (pts) with advanced breast cancer
(ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the
MONALEESA (ML) -3 and -7 trials. Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. June 2020. Chicago, USA.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. O'Shaughnessy J, Stemmer SM, Burris HA, et al. Overall survival subgroup analysis by metastatic
site from the Phase III MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with HR+/HER2- advanced
breast cancer. Presented at the San Antonio Breast Cancer Symposium, December 7-10, 2021. Texas, USA.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14. Kisqali (ribociclib) Prescribing Information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) - Breast Cancer. NCCN Guidelines.
https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Published March 2023. Accessed March 7, 2023.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16. Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast cancer stage at diagnosis and cancer-specific
survival by race and ethnicity in the United States [published correction appears in *JAMA*. 2015 Jun 9;313(22):2287]. *JAMA*.
2015;313(2):165-173. doi:10.1001/jama.2014.17322

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17. American Cancer Society. Treatment of breast cancer stages I -III. Revised April 12, 2022. Accessed
on September 15, 2022. https://www.cancer.org/cancer/breast- cancer/treatment/treatment-of-breast-cancer-by-stage/treatment-of-breast-cancer-stages-i-iii.html

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18. European Society for Medical Oncology – Magnitude of Clinical Benefit Scale Scorecard. https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-158-1.
Published April 20, 2020. Updated August 21, 2020. Accessed September 9, 2020.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19. European Society for Medical Oncology – Magnitude of Clinical Benefit Scale Scorecard. https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-9-1.
Published March 29, 2022. Accessed April 1, 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20. Ribociclib vs. palbociclib in patients with advanced breast cancer within
the HER2-enriched intrinsic subtype (HARMONIA). Identifier NCT05207709. Revised April 4, 2022. Accessed on February 6, 2022. https://clinicaltrials.gov/ct2/show/NCT05207709

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21. Novartis and Vestre Viken Hospital Trust (2022, April 1 – 2024, December 1). Neoadjuvant Treatment
of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole (NEOLETRIB). Identifier NCT05163106. https://clinicaltrials.gov/ct2/show/NCT05163106

\*Ibrance<sup>®</sup> is a registered trademark of Pfizer, Inc.

\# \# \#

---

| | | | |
|:---|:---|:---|:---|
| **Novartis Media Relations**<br> E-mail: media.relations@novartis.com | **Novartis Media Relations**<br> E-mail: media.relations@novartis.com | **Novartis Media Relations**<br> E-mail: media.relations@novartis.com | **Novartis Media Relations**<br> E-mail: media.relations@novartis.com |
| Central |  | &nbsp;&nbsp;&nbsp;&nbsp;North America |  |
| Richard Jarvis | &nbsp;&nbsp;&nbsp;+41 79 584 2326 | &nbsp;&nbsp;&nbsp;&nbsp;Julie Masow | &nbsp;&nbsp;&nbsp;&nbsp;+1 862 579 8456 |
| Anja von Treskow <br> Anna Schäfers | &nbsp;&nbsp;&nbsp; +41 79 392 9697<br> +41 79 801 7267 | &nbsp;&nbsp;&nbsp;&nbsp;Michael Meo <br> Mary Carmichael <br> Marlena Abdinoor | +1 862 274 5414<br> +1 862 200 8344<br> +1 617 335 9525 |
| Switzerland <br> Satoshi Sugimoto | &nbsp;&nbsp;&nbsp; <br> +41 79 619 2035 |  |  |
| **Novartis Investor Relations**<br> Central investor relations line: +41 61 324 7944 <br> E-mail: investor.relations@novartis.com | **Novartis Investor Relations**<br> Central investor relations line: +41 61 324 7944 <br> E-mail: investor.relations@novartis.com | **Novartis Investor Relations**<br> Central investor relations line: +41 61 324 7944 <br> E-mail: investor.relations@novartis.com | **Novartis Investor Relations**<br> Central investor relations line: +41 61 324 7944 <br> E-mail: investor.relations@novartis.com |
| Central |  | &nbsp;&nbsp;&nbsp;&nbsp;North America |  |
| Samir Shah | &nbsp;&nbsp;&nbsp;&nbsp;+41 61 324 7944 | &nbsp;&nbsp;&nbsp;&nbsp;Sloan Simpson | &nbsp;&nbsp;&nbsp;&nbsp;+1 862 345 4440 |
| Nicole Zinsli-Somm | &nbsp;&nbsp;&nbsp;&nbsp;+41 61 324 3809 | &nbsp;&nbsp;&nbsp;&nbsp;Parag Mahanti | &nbsp;&nbsp;&nbsp;&nbsp;+1 973 876 4912 |
| Isabella Zinck | &nbsp;&nbsp;&nbsp;&nbsp;+41 61 324 7188 |  |  |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Novartis AG** | **Novartis AG** |
| Date: March 27, 2023 | By: | /s/ PAUL PENEPENT |
|  | Name: | Paul Penepent |
|  | Title: | Head Group Financial Reporting and Accounting |

---